Puma Biotechnology, Inc. (NASDAQ:PBYI - Get Free Report) crossed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $5.86 and traded as high as $7.02. Puma Biotechnology shares last traded at $6.97, with a volume of 307,008 shares.
Analyst Ratings Changes
PBYI has been the subject of several recent research reports. Weiss Ratings restated a "hold (c+)" rating on shares of Puma Biotechnology in a research note on Thursday, January 22nd. Wall Street Zen upgraded Puma Biotechnology from a "buy" rating to a "strong-buy" rating in a research note on Saturday, March 21st. One research analyst has rated the stock with a Hold rating, According to data from MarketBeat, Puma Biotechnology presently has an average rating of "Hold".
Read Our Latest Stock Report on PBYI
Puma Biotechnology Trading Up 1.2%
The business has a 50-day moving average price of $6.54 and a two-hundred day moving average price of $5.86. The stock has a market capitalization of $354.61 million, a P/E ratio of 11.43 and a beta of 1.19.
Puma Biotechnology (NASDAQ:PBYI - Get Free Report) last released its earnings results on Thursday, February 26th. The biopharmaceutical company reported $0.26 earnings per share for the quarter, beating analysts' consensus estimates of $0.24 by $0.02. Puma Biotechnology had a return on equity of 27.80% and a net margin of 13.62%.The firm had revenue of $75.50 million during the quarter, compared to the consensus estimate of $68.60 million. On average, sell-side analysts forecast that Puma Biotechnology, Inc. will post 0.31 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Puma Biotechnology
Institutional investors have recently modified their holdings of the business. Cerity Partners LLC acquired a new position in shares of Puma Biotechnology during the 2nd quarter worth $36,000. BNP Paribas Financial Markets raised its holdings in shares of Puma Biotechnology by 39.7% during the 3rd quarter. BNP Paribas Financial Markets now owns 8,056 shares of the biopharmaceutical company's stock worth $43,000 after buying an additional 2,290 shares in the last quarter. China Universal Asset Management Co. Ltd. acquired a new position in shares of Puma Biotechnology during the 4th quarter worth $49,000. State of Alaska Department of Revenue acquired a new position in shares of Puma Biotechnology during the 4th quarter worth $50,000. Finally, Caprock Group LLC acquired a new position in shares of Puma Biotechnology during the 3rd quarter worth $59,000. Institutional investors and hedge funds own 61.29% of the company's stock.
Puma Biotechnology Company Profile
(
Get Free Report)
Puma Biotechnology, Inc is a late‐stage biopharmaceutical company dedicated to the development and commercialization of targeted therapies for oncology patients. Founded in 2010 and headquartered in Los Angeles, California, the company focuses on advancing molecularly defined cancer treatments that address significant unmet medical needs.
The company's lead product is neratinib, marketed under the brand name Nerlynx in the United States. Neratinib is an irreversible small‐molecule tyrosine kinase inhibitor designed to target the HER2 receptor, and it received FDA approval in 2017 for extended adjuvant treatment of early‐stage HER2-positive breast cancer.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Puma Biotechnology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Puma Biotechnology wasn't on the list.
While Puma Biotechnology currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
We are about to experience the greatest A.I. boom in stock market history...
Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.
That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.
- The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
- The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
- Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.
Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.
And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...
Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
